Skip to main content
Caplight Logo









Lipo-Immuno Tech

Lipo-Immuno Tech

Private
Mount Pleasant, South CarolinaHealthcare & Life Scienceshttps://lipoimmunotech.com/

Last Round

Accelerator

Apr 22, 2025

Total Funding Raised

$2.02M

Company Overview

Lipo-Immuno Tech is a biotechnology company that develops novel chemo-immunotherapeutic products and T-cell expansion technologies for the treatment of cancer, autoimmune diseases, and neurodegenerative disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologycellular immunotherapycell therapyT-cell expansioncancer therapeuticschemotherapeuticsCAR-T therapydrug discoverylipid metabolismmitochondrial targetingbiotech startupTCR therapyTIL therapypreclinical researchnext-gen cell therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lipo-Immuno Tech Comparables

Compare Lipo-Immuno Tech with similar companies based on industry and business-model similarity.

Lipo-Immuno Tech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SphingoGene, Inc.
76%
Lime Therapeutics
69%
NEOGAP Therapeutics AB
67%

Lipo-Immuno Tech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorApr 22, 2025
GrantApr 4, 2023
GrantApr 4, 2023
GrantApr 30, 2020

Lipo-Immuno Tech Investors

Notable investors and investment history

Lipo-Immuno Tech investors
InvestorRounds
National Cancer InstituteGrant
SCbioDriveAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 4, 2023

    $400K grant from the National Cancer Institute.

  • Apr 4, 2023

    $400K grant from the National Cancer Institute.

Lipo-Immuno Tech Filings

Explore SEC and related filing metadata, where available.

Lipo-Immuno Tech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Lipo-Immuno Tech's valuation, stock price, and market status.

Is Lipo-Immuno Tech a public or private company?

Lipo-Immuno Tech is a private company.

What is the current stock price of Lipo-Immuno Tech?

Lipo-Immuno Tech is a private company with no public stock price. Caplight tracks Lipo-Immuno Tech's secondary market activity and provides MarketPrice estimates to Caplight users.

How much is Lipo-Immuno Tech worth (valuation)?

Valuation information for Lipo-Immuno Tech is not publicly available.

Can I buy Lipo-Immuno Tech stock?

Lipo-Immuno Tech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Lipo-Immuno Tech's last funding round?

Lipo-Immuno Tech's most recent funding round was Accelerator on April 22, 2025.

Who are the main investors in Lipo-Immuno Tech?

Key investors in Lipo-Immuno Tech include National Cancer Institute.

Will Lipo-Immuno Tech IPO soon?

No public IPO plans have been announced for Lipo-Immuno Tech.

How can I track Lipo-Immuno Tech secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Lipo-Immuno Tech's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMount Pleasant, South Carolina
Year Founded2018
Last FundingApr 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?